U.S. License Holder:
AstraZeneca AB
Date of License:
November-14-2017
Last Update:
July-23-2024
FDA-Approved Indications
FASENRA (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.